Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3225)
All Articles published online
|
Mar 14, 2005 (publication date) through Sep 20, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ma JH, Patrut E, Schmidt J, Knaebel HP, Büchler MW, Märten A. Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma. World J Gastroenterol 2005; 11(10): 1521-1528 [PMID: 15770730 DOI: 10.3748/wjg.v11.i10.1521] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i10/1521.htm |
| Number | Citing Articles |
| 1 |
Andrew Sharabi, Joseph Herman, Vivian Weiss, Daniel Laheru, Richard Tuli. Role of radiotherapy in combination with chemotherapy, targeted therapy, and immunotherapy in the management of pancreatic cancer. Journal of Radiation Oncology 2013; 2(4): 369 doi: 10.1007/s13566-013-0125-4
|
| 2 |
Yifan Zhu, Igor Tibensky, Jan Schmidt, Eduard Ryschich, Angela Märten. Interferon-α Enhances Antitumor Effect of Chemotherapy in an Orthotopic Mouse Model for Pancreatic Adenocarcinoma. Journal of Immunotherapy 2008; 31(7): 599 doi: 10.1097/CJI.0b013e3181818769
|
| 3 |
Wen-Jia Wang, Si-Hao Qin, Ji-Wei Zhang, Yue-Yao Jiang, Jin-Nan Zhang, Lei Zhao. Combination Doxorubicin and Interferon-α Therapy Stimulates Immunogenicity of Murine Pancreatic Cancer Panc02 Cells via Up-regulation of NKG2D ligands and MHC Class I. Asian Pacific Journal of Cancer Prevention 2014; 15(22): 9667 doi: 10.7314/APJCP.2014.15.22.9667
|
| 4 |
Christopher J. LaRocca, Joohee Han, Tatyana Gavrikova, Leonard Armstrong, Amanda R. Oliveira, Ryan Shanley, Selwyn M. Vickers, Masato Yamamoto, Julia Davydova. Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer. Surgery 2015; 157(5): 888 doi: 10.1016/j.surg.2015.01.006
|
| 5 |
Stephanie Booy, Leo Hofland, Casper van Eijck. Potentials of Interferon Therapy in the Treatment of Pancreatic Cancer. Journal of Interferon & Cytokine Research 2015; 35(5): 327 doi: 10.1089/jir.2014.0157
|
| 6 |
Angela Märten, Markus W. Büchler, Jan Schmidt. Radiochemoimmunotherapy for pancreatic cancer. The American Journal of Surgery 2007; 194(4): S138 doi: 10.1016/j.amjsurg.2007.05.012
|
| 7 |
Marjolein J.M. Morak, Peter M. van Koetsveld, Roland Kanaar, Leo J. Hofland, Casper H.J. van Eijck. Type I interferons as radiosensitisers for pancreatic cancer. European Journal of Cancer 2011; 47(13): 1938 doi: 10.1016/j.ejca.2011.03.009
|
| 8 |
Jan Schmidt, Dirk Jäger, Kartin Hoffmann, Markus W. Büchler, Angela Märten. Impact of Interferon-α in Combined Chemoradioimmunotherapy for Pancreatic Adenocarcinoma (CapRI): First Data From the Immunomonitoring. Journal of Immunotherapy 2007; 30(1): 108 doi: 10.1097/01.cji.0000211317.15278.27
|
| 9 |
Eva Jöst, Wynand P. Roos, Bernd Kaina, Heinz Schmidberger. Response of pancreatic cancer cells treated with interferon-α or β and co-exposed to ionising radiation. International Journal of Radiation Biology 2010; 86(9): 732 doi: 10.3109/09553002.2010.481321
|
| 10 |
Jan Schmidt, Emilia M. Patrut, Jianhua Ma, Dirk Jäger, Hanns-Peter Knaebel, Markus W. Büchler, Angela Märten. Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI). Cancer Immunology, Immunotherapy 2006; 55(11): 1396 doi: 10.1007/s00262-006-0140-z
|
| 11 |
Angela Märten, Jan Schmidt, Jennifer Ose, Sabine Harig, Ulrich Abel, Marc W Münter, Dirk Jäger, Helmut Friess, Julia Mayerle, Guido Adler, Thomas Seufferlein, Thomas Gress, Roland Schmid, Markus W Büchler. A Randomized Multicentre Phase II Trial Comparing Adjuvant Therapy in Patients with Interferon Alpha-2b and 5-FU Alone or in Combination with Either External Radiation Treatment and Cisplatin (CapRI) or Radiation alone regarding Event-Free Survival – CapRI-2. BMC Cancer 2009; 9(1) doi: 10.1186/1471-2407-9-160
|
| 12 |
Yifan Zhu, Igor Tibensky, Jan Schmidt, Thilo Hackert, Eduard Ryschich, Dirk Jäger, Markus W. Büchler, Angela Märten. Interferon-α in Combination With Chemotherapy has Potent Antiangiogenic Properties in an Orthotopic Mouse Model for Pancreatic Adenocarcinoma. Journal of Immunotherapy 2008; 31(1): 28 doi: 10.1097/CJI.0b013e318157c682
|
| 13 |
Jan Schmidt, Ulrich Abel, Jürgen Debus, Sabine Harig, Katrin Hoffmann, Thomas Herrmann, Detlef Bartsch, Justus Klein, Ulrich Mansmann, Dirk Jäger, Lorenzo Capussotti, Reiner Kunz, Markus W. Büchler. Open-Label, Multicenter, Randomized Phase III Trial of Adjuvant Chemoradiation Plus Interferon Alfa-2b Versus Fluorouracil and Folinic Acid for Patients With Resected Pancreatic Adenocarcinoma. Journal of Clinical Oncology 2012; 30(33): 4077 doi: 10.1200/JCO.2011.38.2960
|
| 14 |
Shuhei Shinoda, Nikita S. Sharma, Naohiko Nakamura, Kazuho Inoko, Mizuho Sato‐Dahlman, Paari Murugan, Julia Davydova, Masato Yamamoto. Interferon‐expressing oncolytic adenovirus + chemoradiation inhibited pancreatic cancer growth in a hamster model. Cancer Science 2023; 114(9): 3759 doi: 10.1111/cas.15903
|